Disitamab vedotin

DB17208InvestigationalProtein Based Therapies

Disitamab vedotin is an antibody-drug conjugate drug targeting human epidermal growth factor receptor 2 (HER2). It is currently being investigated for cancers.

Mechanism: Pharmacologically active on Receptor tyrosine-protein kinase erbB-2
Curator reviewed
Also known as: Vedicitumomab
Code names: PF-08046051 · RC-48 · RC48-ADC

Resolves to

Compound

UNIIRB3U3A1S27CAS2136633-23-1

Targets

P04626ERBB2

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

137Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Disitamab vedotin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account